新辅助化疗联合经口机器人手术治疗人乳头瘤病毒相关口咽癌
这项多中心回顾性队列研究比较了新辅助化疗后经口机器人手术(NECTORS)与同步放化疗(CCRT)治疗人乳头瘤病毒相关口咽鳞状细胞癌(HPV-OPSCC)的无远处转移生存。共纳入342例患者,其中CCRT组232例、NECTORS组110例。匹配后分析显示CCRT组发生远处转移的风险显著高于NECTORS组(多因素分析HR 9.98,95%CI 1.29-77.29),CCRT组任何部位失败的风险也更高(多因素分析HR 3.21,95%CI 1.18-8.72)。作者认为NECTORS是III期和IVa期HPV-OPSCC的有效治疗选择,并建议在前瞻性随机试验中进一步研究。
要点
- 多中心回顾性队列研究比较NECTORS与CCRT治疗III期和IVa期HPV-OPSCC。
- 匹配后CCRT组远处转移风险显著高于NECTORS组(多因素分析HR 9.98,95%CI 1.29-77.29)。
- CCRT组任何部位失败风险也显著高于NECTORS组(多因素分析HR 3.21,95%CI 1.18-8.72)。
核心结论
- 在本研究中,新辅助化疗后经口机器人手术和颈淋巴结清扫是III期和IVa期HPV-OPSCC的有效治疗选择。
- 本研究结果提示NECTORS的远处转移率较低,值得在前瞻性随机试验中进一步研究。
研究设计与样本
- 多中心回顾性队列研究,比较NECTORS治疗组的前瞻性数据与CCRT治疗的历史队列。
- 纳入2010年2月至2021年9月期间接受NECTORS或CCRT治疗的美国癌症联合委员会第七版III期和IVa期HPV-OPSCC患者,共342例,其中282例(82.5%)为男性,平均(标准差)年龄61.4(9.4)岁。
- CCRT组232例,NECTORS组110例;按T和N分期进行伪随机化匹配后,209例患者纳入进一步分析(CCRT组105例,NECTORS组104例)。
- 数据于2024年9月进行分析。
主要发现
- CCRT组中11例(4.7%)发生局部区域复发(LRR),5例(2.2%)发生LRR合并远处转移(DM),28例(12.1%)发生单纯远处转移。
- NECTORS组中5例(4.5%)发生LRR,1例(0.9%)发生LRR合并DM,无患者发生单纯远处转移。
- CCRT组和NECTORS组的中位(范围)随访时间分别为5.8(3.8-7.5)年和5.1(4.0-5.9)年。
- CCRT组发生远处复发的风险比在单因素分析中为10.77(95%CI 1.40-82.90),在多因素分析中为9.98(95%CI 1.29-77.29)。
- CCRT组任何部位失败的风险比在单因素分析中为3.32(95%CI 1.23-8.97),在多因素分析中为3.21(95%CI 1.18-8.72);Kaplan-Meier生存分析显示CCRT组发生DM的风险更高。
关键数值与推荐
- NECTORS方案:3个周期新辅助多西他赛和顺铂化疗,随后行经口机器人手术(TORS)和颈淋巴结清扫。
- CCRT方案:同步高剂量顺铂和放疗。
- 多因素分析校正了年龄、性别、烟草和酒精使用、部位和癌症分期。
临床怎么用
- 作者认为,新辅助化疗后经口机器人手术和颈淋巴结清扫是III期和IVa期HPV-OPSCC的有效治疗选择。
- 作者建议,NECTORS较低的远处转移率值得在前瞻性随机试验中进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Distant metastasis (DM) remains the leading cause of death in patients treated for human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC). An effective treatment strategy needs to address DM while reducing treatment-related toxic effects. OBJECTIVE: To assess DM-free survival in patients with HPV-OPSCC treated with neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection compared with standard of care, concurrent chemoradiation (CCRT). DESIGN, SETTING, AND PARTICIPANTS: This multicenter retrospective cohort study compares prospective data from the NECTORS treatment group with a historical cohort of patients treated with CCRT. Patients with American Joint Committee on Cancer seventh edition stage III and IVa HPV-OPSCC treated with NECTORS and CCRT between February 2010 and September 2021 were included. Data were analyzed in September 2024. EXPOSURES: Patients in the NECTORS arm were treated with 3 cycles of neoadjuvant docetaxel and cisplatin followed by TORS and neck dissection. Patients in the radiation therapy arm were treated with concurrent high-dose cisplatin and radiotherapy. MAIN OUTCOMES AND MEASURES: DM-free survival was analyzed with Kaplan-Meier and Cox regression after adjusting for age, sex, tobacco and alcohol use, site, and cancer stage. RESULTS: Of 342 included patients, 282 (82.5%) were male, and the mean (SD) age was 61.4 (9.4) years. A total of 232 patients were treated with CCRT and 110 patients were treated with NECTORS. Within the CCRT arm, 11 patients (4.7%) had locoregional recurrence (LRR), 5 (2.2%) had LRR and DM, and 28 (12.1%) developed distant-only metastasis. For patients treated with NECTORS, 5 (4.5%) developed LRR, 1 (0.9%) developed LRR plus DM, and no patients developed distant-only metastasis. With pseudorandomization matching for T and N stages, 209 patients were matched between the 2 treatment groups for further analysis (105 in the CCRT treatment arm and 104 in the NECTORS arm). The median (range) follow-up period for the CCRT and NECTORS groups were 5.8 (3.8-7.5) years and 5.1 (4.0-5.9) years, respectively. The hazard ratio of developing distant recurrence in the CCRT group was 10.77 (95% CI, 1.40-82.90) in univariate analysis and 9.98 (95% CI, 1.29-77.29) in multivariable analysis. In Kaplan-Meier survival analysis, the risk of developing DM was higher in the CCRT group. The hazard ratio for failure anywhere in the CCRT group was 3.32 (95% CI, 1.23-8.97) in univariate analysis and 3.21 (95% CI, 1.18-8.72) in multivariable analysis. CONCLUSIONS AND RELEVANCE: In this study, neoadjuvant chemotherapy followed by transoral robotic surgery and neck dissection was an effective treatment option for patients with stage III and IVa HPV-OPSCC. Findings from our study suggest lower rates of DM with NECTORS worthy of further investigation in prospective randomized trials.
引用
- Sadeghi N, Subramaniam T, Richardson K, et al. Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 39636629. doi:10.1001/jamaoto.2024.3303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。